ORCID as entered in ROS

Select Publications
2025, 'Brain transcriptomics highlight abundant gene expression and splicing alterations in non-neuronal cells in aFTLD-U', Acta Neuropathologica, 150, http://dx.doi.org/10.1007/s00401-025-02919-x
,2025, 'Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-59216-0
,2025, 'Dopamine and cortical neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction', Npj Parkinson S Disease, 11, http://dx.doi.org/10.1038/s41531-025-01048-2
,2025, 'Evidence of a novel α-synuclein strain isolated from a Parkinson’s disease with dementia patient sample', Acta Neuropathologica Communications, 13, http://dx.doi.org/10.1186/s40478-025-02093-x
,2025, 'Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy', Translational Neurodegeneration, 14, http://dx.doi.org/10.1186/s40035-025-00469-6
,2025, 'PARKIN protein-deficient iPSC line (FINi006-A) from an early-onset Parkinson's disease female patient', Stem Cell Research, 87, http://dx.doi.org/10.1016/j.scr.2025.103795
,2025, 'Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration.', Elife, 13, http://dx.doi.org/10.7554/eLife.98775
,2025, 'Fourteen years later: Reviewing the diagnostic criteria for behavioral-variant frontotemporal dementia', Alzheimer S and Dementia, 21, http://dx.doi.org/10.1002/alz.70604
,2025, 'Peripheral Mononuclear Cell Mitochondrial Function Associates with T-Cell Cytokines in Parkinson's Disease', Movement Disorders, 40, pp. 1625 - 1635, http://dx.doi.org/10.1002/mds.30233
,2025, 'Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS])', Movement Disorders, 40, pp. 1744 - 1745, http://dx.doi.org/10.1002/mds.30269
,2025, 'Standardised TruAI Automated Quantification of Intracellular Neuromelanin Granules in Human Brain Tissue Sections', Neuropathology and Applied Neurobiology, 51, http://dx.doi.org/10.1111/nan.70033
,2025, 'Alpha-synuclein in Parkinson's disease: Embracing debate, exercising skepticism', Parkinsonism and Related Disorders, 136, http://dx.doi.org/10.1016/j.parkreldis.2025.107874
,2025, 'Dementia with Lewy bodies and Parkinson disease dementia — the same or different and is it important?', Nature Reviews Neurology, 21, pp. 394 - 403, http://dx.doi.org/10.1038/s41582-025-01090-x
,2025, 'Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies', Alzheimer S and Dementia, 21, http://dx.doi.org/10.1002/alz.70470
,2025, 'Neuronal α-synuclein toxicity is the key driver of neurodegeneration in multiple system atrophy', Brain, 148, pp. 2306 - 2319, http://dx.doi.org/10.1093/brain/awaf030
,2025, 'Differences in the soluble and insoluble proteome between primary tauopathies', Alzheimer S and Dementia, 21, http://dx.doi.org/10.1002/alz.70401
,2025, 'Evidence of COMT dysfunction in the olfactory bulb in Parkinson’s disease', Acta Neuropathologica, 149, http://dx.doi.org/10.1007/s00401-025-02861-y
,2025, 'Neuromelanin and selective neuronal vulnerability to Parkinson's disease', Trends in Neurosciences, 48, pp. 445 - 459, http://dx.doi.org/10.1016/j.tins.2025.04.005
,2025, 'Serum neurofilament light is superior to glial fibrillary acidic protein to distinguish sporadic frontotemporal dementia from late-onset primary psychiatric disorders: a retrospective DIPPA-FTD study', BMJ Neurology Open, 7, http://dx.doi.org/10.1136/bmjno-2024-001007
,2025, 'The interactome of tau phosphorylated at T217 in Alzheimer’s disease human brain tissue', Acta Neuropathologica, 149, http://dx.doi.org/10.1007/s00401-025-02881-8
,2025, 'Biological effects of pathologies in Lewy body diseases: why timing matters', Lancet Neurology, 24, pp. 441 - 455, http://dx.doi.org/10.1016/S1474-4422(25)00085-7
,2025, 'hnRNP A1, hnRNP A2B1, and hnRNP K are dysregulated in tauopathies, but do not colocalize with tau pathology', Brain Pathology, 35, http://dx.doi.org/10.1111/bpa.13305
,2025, 'Human Endogenous Retrovirus K in Astrocytes Is Altered in Parkinson's Disease', Movement Disorders, 40, pp. 683 - 692, http://dx.doi.org/10.1002/mds.30128
,2025, 'Reduced plasma hexosylceramides in frontotemporal dementia are a biomarker of white matter integrity', Alzheimer S and Dementia Diagnosis Assessment and Disease Monitoring, 17, http://dx.doi.org/10.1002/dad2.70131
,2025, 'Future is now: An Australasian perspective on disease-modifying trials in Parkinson's and prodromal disease', BMJ Neurology Open, 7, http://dx.doi.org/10.1136/bmjno-2025-001070
,2025, 'A Call for Change: Updating the Operational Definition for Dementia in Parkinson's Disease', Movement Disorders Clinical Practice, 12, pp. 296 - 301, http://dx.doi.org/10.1002/mdc3.14305
,2025, 'Number of Carbons Is a Critical Parameter for Accumulation of Per- and Polyfluoroalkyl Substances in the Human Brain', Environmental Science and Technology, 59, pp. 3366 - 3375, http://dx.doi.org/10.1021/acs.est.4c09458
,2025, 'Erratum: Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions (Neuron (2024) 112(17) (2886–2909.e16), (S0896627324004094), (10.1016/j.neuron.2024.06.002))', Neuron, 113, pp. 637, http://dx.doi.org/10.1016/j.neuron.2025.01.018
,2025, 'The α-synuclein seed amplification assay: Interpreting a test of Parkinson's pathology', Parkinsonism and Related Disorders, 131, http://dx.doi.org/10.1016/j.parkreldis.2024.107256
,2025, 'Multiple System Atrophy: Pathology, Pathogenesis, and Path Forward', Annual Review of Pathology Mechanisms of Disease, 20, pp. 245 - 273, http://dx.doi.org/10.1146/annurev-pathmechdis-051122-104528
,2025, 'Behavioral subtypes impact prognosis and survival in amyotrophic lateral sclerosis: a clustering-based approach', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, http://dx.doi.org/10.1080/21678421.2025.2522402
,2025, 'Differentiating sporadic frontotemporal dementia from late-onset primary psychiatric disorders', Brain Communications, 7, http://dx.doi.org/10.1093/braincomms/fcaf199
,2025, 'Distinct AQP4 Alterations in Movement Disorders with Primary Synucleinopathy', Movement Disorders, http://dx.doi.org/10.1002/mds.70023
,2025, 'Dysregulation of Monounsaturated Fatty Acids is Related to α-Synuclein in Multiple System Atrophy', Movement Disorders, http://dx.doi.org/10.1002/mds.30248
,2025, 'Mitochondrial impairments in mononuclear cells are associated with inflammation in Parkinson’s disease.', Parkinsonism & Related Disorders, 134, pp. 107422 - 107422, http://dx.doi.org/10.1016/j.parkreldis.2025.107422
,2024, 'A new seed amplification assay to diagnose multiple system atrophy', Lancet Neurology, 23, pp. 1175 - 1176, http://dx.doi.org/10.1016/S1474-4422(24)00428-9
,2024, 'A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells', Npj Parkinson S Disease, 10, http://dx.doi.org/10.1038/s41531-023-00624-8
,2024, 'A protective role of ABCA5 in response to elevated sphingomyelin levels in Parkinson’s disease', Npj Parkinson S Disease, 10, http://dx.doi.org/10.1038/s41531-024-00632-2
,2024, 'Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model', Translational Neurodegeneration, 13, http://dx.doi.org/10.1186/s40035-024-00448-3
,2024, 'Biomarker-Based Approach to α-Synucleinopathies: Lessons from Neuropathology', Movement Disorders, 39, pp. 2173 - 2179, http://dx.doi.org/10.1002/mds.30028
,2024, 'Letter to the editor on: Hornerin deposits in neuronal intranuclear inclusion disease: direct identification of proteins with compositionally biased regions in inclusions by Park et al. (2022)', Acta Neuropathologica Communications, 12, http://dx.doi.org/10.1186/s40478-023-01706-7
,2024, 'MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity', Npj Parkinson S Disease, 10, http://dx.doi.org/10.1038/s41531-024-00841-9
,2024, 'N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson’s disease', Translational Neurodegeneration, 13, http://dx.doi.org/10.1186/s40035-024-00456-3
,2024, 'Prediction of motor and non-motor Parkinson’s disease symptoms using serum lipidomics and machine learning: a 2-year study', Npj Parkinson S Disease, 10, http://dx.doi.org/10.1038/s41531-024-00741-y
,2024, 'SMOC1 colocalizes with Alzheimer’s disease neuropathology and delays Aβ aggregation', Acta Neuropathologica, 148, http://dx.doi.org/10.1007/s00401-024-02819-6
,2024, 'Research Priorities on the Role of α-Synuclein in Parkinson's Disease Pathogenesis', Movement Disorders, 39, pp. 1663 - 1678, http://dx.doi.org/10.1002/mds.29897
,2024, 'Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions', Neuron, 112, pp. 2886 - 2909.e16, http://dx.doi.org/10.1016/j.neuron.2024.06.002
,2024, '⍺-Synuclein levels in Parkinson's disease – Cell types and forms that contribute to pathogenesis', Experimental Neurology, 379, http://dx.doi.org/10.1016/j.expneurol.2024.114887
,2024, 'Poly-GA immunohistochemistry is a reliable tool for detecting C9orf72 hexanucleotide repeat expansions', Brain Pathology, 34, http://dx.doi.org/10.1111/bpa.13216
,2024, 'Risk factors for the neurodegenerative dementias in the Western Pacific region', Lancet Regional Health Western Pacific, 50, http://dx.doi.org/10.1016/j.lanwpc.2024.101051
,